热线电话:+86 512 6799 8818

在线咨询

TOP

*姓名

*电话

邮箱

咨询内容

*验证码

联系销售


Sales Image

联系销售助理


Sales Assistant Image

联系PM


PM Image
Consult Now
GentleGen's Complete Guide to RNA Experiments: Key Points for Cell Death, Silence Failure, and Quality Control
2026-10-08
GentleGen's Complete Guide to RNA Experiments: Key Points for Cell Death, Silence Failure, and Quality Control
GentleGen's RNA Experiment Playbook — your guide to troubleshooting cell death, silencing failure, and QC in siRNA/ASO transfection.
View More
GentleGen Observation | Mythos 5.1 Hit Rate Nearly 50%: No matter how strong large models are, wet experiments remain the gold standard for macromolecules
2026-09-29
GentleGen Observation | Mythos 5.1 Hit Rate Nearly 50%: No matter how strong large models are, wet experiments remain the gold standard for macromolecules
Anthropic's Mythos 5.1 achieved nearly 50% hit rate in wet-lab protein design, yet wet-lab validation remains essential. GentleGen provides a dry-wet closed loop with an automated high-throughput platform, from gene synthesis to affinity detection, empowering AI antibody development.
View More
GentleGen Observation | GB-0895 Enters Phase III! What insights does generative AI bring from scratch designing antibodies?
2026-09-29
GentleGen Observation | GB-0895 Enters Phase III! What insights does generative AI bring from scratch designing antibodies?
GentleGen Observations: Generate Biomedicines' AI‑designed anti‑TSLP antibody GB‑0895 is now in Phase III — dosed just once every six months — a powerful validation of the "generative AI + wet‑lab closed loop" path. GentleGen offers high‑throughput antibody expression and affinity measurement to help close the dry‑wet loop.
View More
From AI Design to Affinity Representation: GentleGen Supports "The Changjiang Cup 2026 Global AI Protein Design Challenge"
2026-09-29
From AI Design to Affinity Representation: GentleGen Supports "The Changjiang Cup 2026 Global AI Protein Design Challenge"
GentleGen sponsors "The Changjiang Cup 2026 Global AI Protein Design Challenge", providing high‑throughput wet‑lab validation to help AI‑designed proteins move from computation to reality. The competition offers a prize pool of one million RMB, with registration open until October 31.
View More
In the AIDD Era: How GentleGen Bridges the Last Mile of AI Drug Discovery
2026-09-24
In the AIDD Era: How GentleGen Bridges the Last Mile of AI Drug Discovery
In the AIDD era, GentleGen and Wecomput have joined forces. With fully automated wet‑lab validation, they're bridging the "last mile" of AI drug discovery—creating a seamless dry‑wet loop of "AI design → automated validation → data feedback" so that AI‑designed candidates can quickly be tested against real experimental data.
View More
From antibody discovery to IND application, how does GentleGen handle antibody drug R&D in one stop?
2026-09-20
From antibody discovery to IND application, how does GentleGen handle antibody drug R&D in one stop?
From antibody discovery and sequencing to high‑throughput expression, affinity measurement (ELISA/BLI/SPR), and safety assessment—GentleGen's fully automated platform delivers a true one‑stop antibody drug development solution, covering everything from early screening to IND submission.
View More
GentleGen NGS Platform - mRNA Drug Safety Evaluation: Full-chain sequence validation from plasmids to mRNA
2026-09-17
GentleGen NGS Platform - mRNA Drug Safety Evaluation: Full-chain sequence validation from plasmids to mRNA
GentleGen's NGS platform offers mRNA drug safety evaluation services, covering full-chain sequence verification from plasmid to mRNA. It also introduces the NGSafety™ platform, which has supported multiple CGT clients in successfully filing IND applications in both China and the U.S.
View More
GentleGen's CRISPR-Screen-NGS guide: from massive genes to key targets
2026-09-14
GentleGen's CRISPR-Screen-NGS guide: from massive genes to key targets
GentleGen's CRISPR‑Screen‑NGS Guide breaks down library QC, sequencing depth, and positive/negative screening strategies. With one‑stop gRNA library services delivering ≥99% coverage and <10 uniformity, we help you zero in on critical targets from thousands of genes.
View More
GentleGen RNA Synthesis White Paper: From Chemical Synthesis to Enzymatic Ligation, From Sequences to Drugs
2026-09-11
GentleGen RNA Synthesis White Paper: From Chemical Synthesis to Enzymatic Ligation, From Sequences to Drugs
GentleGen's RNA Synthesis White Paper breaks down the three main routes—chemical synthesis, IVT, and enzymatic ligation—and dives deep into modification strategies across the sugar, backbone, base, and conjugation. With nearly 100 modifications available, GentleGen's RNA synthesis services are here to accelerate your small nucleic acid drug development.
View More
[Client Article Interpretation] GentleGen empowers knock down Cryaa and reveals new XLRP mechanism
2026-09-08
[Client Article Interpretation] GentleGen empowers knock down Cryaa and reveals new XLRP mechanism
This study reveals that downregulation of Cryaa (HspB4) in rd9 mice triggers the unfolded protein response (UPR) pathway, which subsequently drives photoreceptor cell apoptosis, providing new insights into the pathogenesis of X-linked retinitis pigmentosa (XLRP). GentleGen provided control support for the Cryaa-targeting siRNA used in this research.
View More
12345
Pre-sales consulting

Pre-sales consulting

A more reliable solution for your needs.
Download

Download

Welcome to our product library.
Sales network

Sales network

Complete sales and service network to ensure product quality.
Event Promotions

Event Promotions

Add to cart now and enjoy this shopping extravaganza!